Pharma shares hit over 2,000 lawsuits in US over Zantac heartburn tablets

Heartburn drug was pulled from the market in 2020 for containing a probable carcinogen

Shares in GSK, Sanofi and Haleon have been hit following US lawsuits over Zantac   

Shares in GSK, Sanofi, and Haleon fell sharply, building on declines earlier this week, amid growing concerns about US litigation over a heartburn drug that was pulled from the market in 2020 for containing a probable carcinogen.

GSK shares tumbled over 9%, Sanofi's shares fell by 8%, and shares in Haleon, which had recently been spun out of GSK's consumer health unit, fell 4% at one stage on Thursday.